NZ537220A - Method of isolating an endothelial cell and method of donor specific crossmatching - Google Patents
Method of isolating an endothelial cell and method of donor specific crossmatchingInfo
- Publication number
- NZ537220A NZ537220A NZ537220A NZ53722003A NZ537220A NZ 537220 A NZ537220 A NZ 537220A NZ 537220 A NZ537220 A NZ 537220A NZ 53722003 A NZ53722003 A NZ 53722003A NZ 537220 A NZ537220 A NZ 537220A
- Authority
- NZ
- New Zealand
- Prior art keywords
- endothelial cell
- sample
- cells
- tie
- isolated
- Prior art date
Links
- 210000002889 endothelial cell Anatomy 0.000 title claims abstract description 111
- 238000000034 method Methods 0.000 title claims abstract description 58
- 210000004027 cell Anatomy 0.000 claims abstract description 98
- 210000004369 blood Anatomy 0.000 claims abstract description 22
- 239000008280 blood Substances 0.000 claims abstract description 22
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims description 74
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims description 73
- 239000000523 sample Substances 0.000 claims description 53
- 238000001514 detection method Methods 0.000 claims description 39
- 239000002243 precursor Substances 0.000 claims description 34
- 239000003153 chemical reaction reagent Substances 0.000 claims description 29
- 230000009257 reactivity Effects 0.000 claims description 20
- 239000011324 bead Substances 0.000 claims description 19
- 230000005291 magnetic effect Effects 0.000 claims description 19
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 19
- 239000012472 biological sample Substances 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 10
- 102000000844 Cell Surface Receptors Human genes 0.000 claims description 8
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 8
- 238000000684 flow cytometry Methods 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 230000005298 paramagnetic effect Effects 0.000 claims description 6
- 102000009840 Angiopoietins Human genes 0.000 claims description 5
- 108010009906 Angiopoietins Proteins 0.000 claims description 5
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 230000001464 adherent effect Effects 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 claims 1
- 238000012606 in vitro cell culture Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 abstract description 13
- 210000000056 organ Anatomy 0.000 abstract description 12
- 238000002955 isolation Methods 0.000 abstract description 9
- 230000002482 anti-endothelial effect Effects 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 description 17
- 208000019553 vascular disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000003511 endothelial effect Effects 0.000 description 10
- 208000023275 Autoimmune disease Diseases 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 206010059245 Angiopathy Diseases 0.000 description 8
- 208000026278 immune system disease Diseases 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 238000004393 prognosis Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 5
- 108010022164 acetyl-LDL Proteins 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 102100036537 von Willebrand factor Human genes 0.000 description 5
- 108020003285 Isocitrate lyase Proteins 0.000 description 4
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 108091008605 VEGF receptors Proteins 0.000 description 4
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 4
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000003365 immunocytochemistry Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000010445 mica Substances 0.000 description 4
- 229910052618 mica group Inorganic materials 0.000 description 4
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 4
- 108010047303 von Willebrand Factor Proteins 0.000 description 4
- 229960001134 von willebrand factor Drugs 0.000 description 4
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 150000002736 metal compounds Chemical class 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 239000011435 rock Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 102100023471 E-selectin Human genes 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102100025136 Macrosialin Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010048748 Graft loss Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108010031034 MHC class I-related chain A Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000012753 TIE-2 Receptor Human genes 0.000 description 1
- 108010090091 TIE-2 Receptor Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000006177 biological buffer Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 210000002358 circulating endothelial cell Anatomy 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000007822 cytometric assay Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 231100000355 lymphocytotoxic Toxicity 0.000 description 1
- 230000001391 lymphocytotoxic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000011140 membrane chromatography Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38103302P | 2002-05-16 | 2002-05-16 | |
| PCT/IB2003/002502 WO2003098212A2 (en) | 2002-05-16 | 2003-05-16 | Method of isolating an endotehelial cell and method of donor specific crossmatching |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ537220A true NZ537220A (en) | 2008-06-30 |
Family
ID=29550055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ537220A NZ537220A (en) | 2002-05-16 | 2003-05-16 | Method of isolating an endothelial cell and method of donor specific crossmatching |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8173372B2 (enExample) |
| EP (1) | EP1458853B1 (enExample) |
| AT (1) | ATE449838T1 (enExample) |
| AU (1) | AU2003241107B2 (enExample) |
| BR (1) | BRPI0311182A2 (enExample) |
| CA (1) | CA2486119C (enExample) |
| CY (1) | CY1109815T1 (enExample) |
| DE (1) | DE60330223D1 (enExample) |
| DK (1) | DK1458853T3 (enExample) |
| ES (1) | ES2337244T3 (enExample) |
| IL (2) | IL165250A0 (enExample) |
| NO (1) | NO20040174L (enExample) |
| NZ (1) | NZ537220A (enExample) |
| PL (2) | PL397820A1 (enExample) |
| PT (1) | PT1458853E (enExample) |
| SI (1) | SI1458853T1 (enExample) |
| WO (1) | WO2003098212A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8980568B2 (en) | 2001-10-11 | 2015-03-17 | Aviva Biosciences Corporation | Methods and compositions for detecting non-hematopoietic cells from a blood sample |
| US8986944B2 (en) | 2001-10-11 | 2015-03-24 | Aviva Biosciences Corporation | Methods and compositions for separating rare cells from fluid samples |
| NZ537220A (en) * | 2002-05-16 | 2008-06-30 | Absorber Ab | Method of isolating an endothelial cell and method of donor specific crossmatching |
| CA2657621A1 (en) | 2006-07-14 | 2008-01-17 | Aviva Biosciences Corporation | Methods and compositions for detecting rare cells from a biological sample |
| EP2051076A1 (en) * | 2007-10-18 | 2009-04-22 | Koninklijke Philips Electronics N.V. | Interaction of probe molecules and cells as a diagnostic marker |
| KR20220131293A (ko) | 2020-01-24 | 2022-09-27 | 화이자 인코포레이티드 | 항-e-셀렉틴 항체, 조성물 및 사용 방법 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
| US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
| NO155316C (no) | 1982-04-23 | 1987-03-11 | Sintef | Fremgangsmaate for fremstilling av magnetiske polymerpartikler. |
| US4965204A (en) | 1984-02-06 | 1990-10-23 | The Johns Hopkins University | Human stem cells and monoclonal antibodies |
| US5130144B1 (en) | 1984-02-06 | 1995-08-15 | Univ Johns Hopkins | Human stem cells and monoclonal antibodies |
| US4714680B1 (en) * | 1984-02-06 | 1995-06-27 | Univ Johns Hopkins | Human stem cells |
| US5026365A (en) | 1987-04-29 | 1991-06-25 | The University Of Massachusetts | Method and apparatus for therapeutically treating immunological disorders and disease states |
| ATE81724T1 (de) | 1987-11-09 | 1992-11-15 | Becton Dickinson Co | Verfahren zur analyse haematopoietischer zellen in einer probe. |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US5071741A (en) | 1988-04-18 | 1991-12-10 | Cryolife, Inc. | Cryoprotective agent and its use in cryopreservation of cellular matter |
| DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
| DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
| US5084350A (en) | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5283058A (en) | 1990-08-30 | 1994-02-01 | The General Hospital Corporation | Methods for inhibiting rejection of transplanted tissue |
| SG47470A1 (en) | 1991-04-25 | 1998-04-17 | Univ Brown Res Found | Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products |
| US5257984A (en) | 1991-10-02 | 1993-11-02 | Norfolk Scientific, Inc. | Blood collector |
| US5955291A (en) * | 1992-01-09 | 1999-09-21 | Alitalo; Kari | Antibodies recognizing tie receptor tyrosine kinase and uses thereof |
| IL104470A0 (en) | 1992-01-21 | 1993-05-13 | Cryopharm Corp | Process for freezing cells and cell like materials and compositions prepared thereby |
| US5518890A (en) | 1992-11-20 | 1996-05-21 | Mccormick & Company, Inc. | Method and apparatus for the quantitation and separation of contaminants from particulate materials |
| ES2178654T3 (es) | 1993-08-12 | 2003-01-01 | Neurotech Sa | Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas. |
| US5518878A (en) | 1993-09-15 | 1996-05-21 | Organogenesis Inc. | Cryopreservation of cultured skin or cornea equivalents with agitation |
| US5482841A (en) | 1994-05-24 | 1996-01-09 | Sangstat Medical Corporation | Evaluation of transplant acceptance |
| US6017719A (en) * | 1994-06-14 | 2000-01-25 | Nexell Therapeutics, Inc. | Positive and positive/negative cell selection mediated by peptide release |
| US5840502A (en) * | 1994-08-31 | 1998-11-24 | Activated Cell Therapy, Inc. | Methods for enriching specific cell-types by density gradient centrifugation |
| US5580714A (en) | 1995-03-08 | 1996-12-03 | Celox Laboratories, Inc. | Cryopreservation solution |
| US5629145A (en) | 1995-03-24 | 1997-05-13 | Organ, Inc. | Cryopreservation of cell suspensions |
| KR0176513B1 (ko) * | 1995-04-13 | 1999-04-15 | 김광호 | 자기 기록/재생장치 |
| US5942385A (en) * | 1996-03-21 | 1999-08-24 | Sugen, Inc. | Method for molecular diagnosis of tumor angiogenesis and metastasis |
| US5843633A (en) * | 1996-04-26 | 1998-12-01 | Amcell Corporation | Characterization of a human hematopoietic progenitor cell antigen |
| WO1998014058A1 (en) | 1996-10-03 | 1998-04-09 | The Regents Of The University Of California | Cryopreservation of human adult and fetal pancreatic cells and human platelets |
| US6103536A (en) | 1997-05-02 | 2000-08-15 | Silver Lake Research Corporation | Internally referenced competitive assays |
| EP0893493A3 (de) * | 1997-07-21 | 2002-12-04 | Aventis Pharma Deutschland GmbH | Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen |
| US20030100107A1 (en) | 1998-05-29 | 2003-05-29 | Thomas Jefferson University | Compositions and methods for generating differentiated human cells |
| US6376653B1 (en) | 1998-09-28 | 2002-04-23 | Smithkline Beecham Plc | Tie2 antagonist antibodies |
| US6197294B1 (en) | 1998-10-26 | 2001-03-06 | Neurotech S.A. | Cell surface molecule-induced macrophage activation |
| US6309643B1 (en) | 1999-04-30 | 2001-10-30 | The Regents Of The University Of California | IBD-associated microbial antigens and methods of using same |
| GB0015923D0 (en) * | 2000-06-30 | 2000-08-23 | Astrazeneca Ab | Methods |
| US6984308B2 (en) * | 2001-03-06 | 2006-01-10 | Cincinnati Children's Hospital Research Foundation | Electrochemical analysis of coenzyme Q10 and reduced coenzyme Q10 |
| US20050026220A1 (en) * | 2001-08-10 | 2005-02-03 | Shahin Rafii | Isolation and mobilization of stem cells expressing vegfr-1 |
| WO2003062373A2 (en) * | 2001-10-18 | 2003-07-31 | The Children's Hospital Of Philadelphia | Methods and materials for the recruitment of endothelial cells |
| NZ537220A (en) * | 2002-05-16 | 2008-06-30 | Absorber Ab | Method of isolating an endothelial cell and method of donor specific crossmatching |
| JP2008509678A (ja) * | 2004-08-13 | 2008-04-03 | メドトロニック・インコーポレーテッド | 内皮前駆細胞サブセットの単離とそれらの使用方法 |
-
2003
- 2003-05-16 NZ NZ537220A patent/NZ537220A/en not_active IP Right Cessation
- 2003-05-16 EP EP03730427A patent/EP1458853B1/en not_active Expired - Lifetime
- 2003-05-16 AT AT03730427T patent/ATE449838T1/de active
- 2003-05-16 US US10/439,666 patent/US8173372B2/en not_active Expired - Fee Related
- 2003-05-16 BR BRPI0311182A patent/BRPI0311182A2/pt not_active IP Right Cessation
- 2003-05-16 CA CA2486119A patent/CA2486119C/en not_active Expired - Fee Related
- 2003-05-16 PT PT03730427T patent/PT1458853E/pt unknown
- 2003-05-16 WO PCT/IB2003/002502 patent/WO2003098212A2/en not_active Ceased
- 2003-05-16 SI SI200331742T patent/SI1458853T1/sl unknown
- 2003-05-16 DE DE60330223T patent/DE60330223D1/de not_active Expired - Lifetime
- 2003-05-16 DK DK03730427.6T patent/DK1458853T3/da active
- 2003-05-16 PL PL397820A patent/PL397820A1/pl not_active Application Discontinuation
- 2003-05-16 PL PL373564A patent/PL212661B1/pl not_active IP Right Cessation
- 2003-05-16 IL IL16525003A patent/IL165250A0/xx active IP Right Grant
- 2003-05-16 AU AU2003241107A patent/AU2003241107B2/en not_active Ceased
- 2003-05-16 ES ES03730427T patent/ES2337244T3/es not_active Expired - Lifetime
-
2004
- 2004-01-15 NO NO20040174A patent/NO20040174L/no not_active Application Discontinuation
- 2004-11-16 IL IL165250A patent/IL165250A/en unknown
-
2005
- 2005-05-16 US US11/130,306 patent/US20050244404A1/en not_active Abandoned
-
2008
- 2008-12-02 US US12/326,547 patent/US8034635B2/en not_active Expired - Fee Related
-
2010
- 2010-02-12 CY CY20101100147T patent/CY1109815T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20030228638A1 (en) | 2003-12-11 |
| US20050244404A1 (en) | 2005-11-03 |
| ATE449838T1 (de) | 2009-12-15 |
| PT1458853E (pt) | 2010-02-23 |
| PL397820A1 (pl) | 2012-07-16 |
| WO2003098212A2 (en) | 2003-11-27 |
| CA2486119C (en) | 2011-01-04 |
| NO20040174L (no) | 2004-03-08 |
| DK1458853T3 (da) | 2010-04-06 |
| US8034635B2 (en) | 2011-10-11 |
| US20090142780A1 (en) | 2009-06-04 |
| DE60330223D1 (enExample) | 2010-01-07 |
| EP1458853A2 (en) | 2004-09-22 |
| SI1458853T1 (sl) | 2010-04-30 |
| AU2003241107A1 (en) | 2003-12-02 |
| ES2337244T3 (es) | 2010-04-22 |
| US8173372B2 (en) | 2012-05-08 |
| PL373564A1 (en) | 2005-09-05 |
| EP1458853B1 (en) | 2009-11-25 |
| WO2003098212B1 (en) | 2004-07-29 |
| CY1109815T1 (el) | 2014-09-10 |
| PL212661B1 (pl) | 2012-11-30 |
| CA2486119A1 (en) | 2003-11-27 |
| IL165250A0 (en) | 2005-12-18 |
| IL165250A (en) | 2011-03-31 |
| WO2003098212A3 (en) | 2004-07-01 |
| BRPI0311182A2 (pt) | 2016-06-21 |
| AU2003241107B2 (en) | 2009-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bishop et al. | Immunopathology of renal allograft rejection analyzed with monoclonal antibodies to mononuclear cell markers | |
| George et al. | Rapid isolation of human endothelial cells from whole blood using S-Endo1 monoclonal antibody coupled to immuno-magnetic beads: demonstration of endothelial injury after angioplasty | |
| McKenna et al. | ANTI-HLA ANTIBODIES AFTER SOLID ORGAN TRANSPLANTATION1 | |
| Hodkinson et al. | Preliminary evidence of immune function modulation by thyroid hormones in healthy men and women aged 55–70 years | |
| JP4450998B2 (ja) | フローサイトメトリの全血樹状細胞免疫機能アッセイ | |
| Caforio et al. | Inappropriate major histocompatibility complex expression on cardiac tissue in dilated cardiomyopathy. Relevance for autoimmunity? | |
| Aras et al. | Induction of microparticle-and cell-associated intravascular tissue factor in human endotoxemia | |
| US8034635B2 (en) | Methods of donor specific crossmatching | |
| US20100008932A1 (en) | Use of soluble cd160 to suppress immunity | |
| Vermehren et al. | Isolation of precursor endothelial cells from peripheral blood for donor-specific crossmatching before organ transplantation | |
| Tugulea et al. | NEW STRATEGIES FOR EARLY DIAGNOSIS OF HEART ALLOGRAFT REJECTION1 | |
| JP3550410B2 (ja) | 好塩基球に結合するモノクローナル抗体、好塩基球の分離方法、好塩基球からのケミカルメディエーターの遊離方法、及び好塩基球由来ケミカルメディエーター遊離試験法 | |
| Kamali et al. | Sensing acute cellular rejection in liver transplant patients using liver-derived extracellular particles: a prospective, observational study | |
| Nagaeva et al. | An optimized technique for separation of human decidual leukocytes for cellular and molecular analyses | |
| Richards et al. | Analysis of T cells in paroxysmal nocturnal hemoglobinuria provides direct evidence that thymic T-cell production declines with age | |
| Moghaddami et al. | Recruitment of dendritic cells and macrophages during T cell-mediated synovial inflammation | |
| Fuggle | Immunophenotypic analysis of leukocyte infiltration in the renal transplant | |
| US6949346B2 (en) | Method for binding basophils and mast cells | |
| EP4189070A1 (en) | Novel t cells and the uses thereof | |
| Snelgrove et al. | T‐cell receptor αβ+ double‐negative T cells in the kidney are predominantly extravascular and increase in abundance in response to ischemia–reperfusion injury | |
| US20130177925A1 (en) | Detection of antigen-specific peripheral blood mononuclear cells and methods for diagnosing immune disorders | |
| Stastny et al. | Evaluation of the highly sensitized transplant recipient | |
| US20040029554A1 (en) | Method for histocompatibility testing | |
| Joshi et al. | Applications of Flow Cytometry in Transplant Medicine | |
| WO1995014230A1 (en) | Marker for crohn's disease and multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 MAY 2016 BY LEA SKYLLERSTEDT Effective date: 20130417 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAY 2017 BY LEA SKYLLERSTEDT Effective date: 20160427 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAY 2018 BY CPA GLOBAL (PATRAFEE) Effective date: 20170503 |
|
| LAPS | Patent lapsed |